Showing results (81-90 of 94) with videos related to
Sort By:
Pageof 10
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|February 20, 2007
Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paperEric Macy, Jonathan A Bernstein, Mariana C Castells, et al.The Journal of Allergy and Clinical Immunology. in Practice|November 3, 2024
AAAAI Position Statement on Changing Electronic Health Record Allergy Documentation to "Alerts" to Lead to Easily Understood, Actionable LabelsAndrew A White, Allison Ramsey, Autumn Guyer, et al.The Journal of Allergy and Clinical Immunology. in Practice|September 25, 2018
Controversies in Drug Allergy: Beta-Lactam Hypersensitivity TestingMaria J Torres, N Franklin Adkinson, Jean-Christoph Caubet, et al.The Journal of Allergy and Clinical Immunology. in Practice|September 23, 2022
Allergy Electronic Health Record Documentation: A 2022 Work Group Report of the AAAAI Adverse Reactions to Drugs, Biologicals, and Latex CommitteeAutumn C Guyer, Eric Macy, Andrew A White, et al.JAMA Network Open|July 15, 2021
High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use DisorderAndrew A Herring, Aidan A Vosooghi, Joshua Luftig, et al.Addiction (Abingdon, England)|January 20, 2009
Buprenorphine tapering schedule and illicit opioid useWalter Ling, Maureen Hillhouse, Catherine Domier, et al.The Journal of Biological Chemistry|May 21, 2004
Co-aggregation of FcgammaRII with FcepsilonRI on human mast cells inhibits antigen-induced secretion and involves SHIP-Grb2-Dok complexesChristopher L Kepley, Sharven Taghavi, Graham Mackay, et al.Annals of Internal Medicine|March 21, 2022
The Management of Substance Use Disorders: Synopsis of the 2021 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice GuidelineChristopher Perry, Joseph Liberto, Charles Milliken, et al.The Journal of Allergy and Clinical Immunology|October 24, 2007
A mouse Fcgamma-Fcepsilon protein that inhibits mast cells through activation of FcgammaRIIB, SH2 domain-containing inositol phosphatase 1, and SH2 domain-containing protein tyrosine phosphatasesElisabeth Mertsching, Lisa Bafetti, Henry Hess, et al.Journal of Substance Abuse Treatment|March 24, 2010
From research to the real world: buprenorphine in the decade of the Clinical Trials NetworkWalter Ling, Petra Jacobs, Maureen Hillhouse, et al.Pageof 10